This article has now been retracted and a retraction statement has been published.
Retracted: Sponsored Content: Optimising ▼Enfortumab Vedotin + Pembrolizumab in Comorbid Patients with Unresectable or Metastatic Urothelial Carcinoma
- Author:
-
* Nick Ellis 1
- Contributors:
Giuseppe Fornarini,2 Carole Helissey,3 Robert Jones,4 Vadim Koshkin,5 Dora Niedersüß-Beke,6 Javier Puente,7 Michiel Simon van der Heijden,8 Gunhild von Amsberg9
2. IRCCS Policlinico San Martino Genova, Italy
3. Clinical Research Unit, HIA BEGIN, Department of Radiation Biological Effects, French Armed Forces Biomedical Research Institute, Brétigny-sur-Orge, France
4. Beatson West of Scotland Cancer Centre, Glasgow, UK
5. University of California, San Francisco, USA
6. Center for Oncology, Hematology and Palliative Medicine, Wilhelminenspital Montleartstraße, Vienna, Austria
7. Hospital Clinico Universitario San Carlos, Madrid, Spain
8. Netherlands Cancer Institute (NKI), Amsterdam, the Netherlands
9. Martini Clinic University Medical Center, Hamburg, Germany- Disclosure:
All contributors have received honoraria from Astellas Pharma Ltd and have declared no conflicts of interest.
- Acknowledgements:
Medical writing and editorial support were provided by OPEN Health Medical Communications, London, UK, and funded by Astellas Pharma Ltd, in accordance with Good Publication Practice (GPP) guidelines.
- Disclaimer:
Astellas Pharma Ltd also had editorial input in the writing of this publication. The publisher retained final editorial control of the content. The opinions expressed are not necessarily those of the publisher.
Date of preparation: September 2025 | MAT-GB-PAD-2025-00234
Prescribing information for PADCEV™▼(enfortumab vedotin) is available at the end of this article.
Indication: PADCEV™ (enfortumab vedotin), in combination with pembrolizumab, is indicated for the first-line treatment of adult patients with unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy.
PADCEV™(enfortumab vedotin) as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor-1 or programmed death-ligand 1 inhibitor.
▼This medicinal product is subject to additional monitoring.
- Support:
The publication of this article has been supported by Astellas Pharma Ltd.
- Received:
- 01.07.25
- Accepted:
- 07.08.25
- Citation:
- Keywords:
- Comorbidity, enfortumab vedotin (EV), frail, guidance, management, metastatic urothelial carcinoma (mUC), pembrolizumab.
Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.
